Importantly, BHD syndrome is one of the mammalian target of rapamycin (mTOR) pathway diseases, a group of rare genetic diseases sharing a common underlying molecular basis and providing the opportunity to combine basic and translational research as well as collaboration between basic scientists and clinicians [7]. The gene discussed is MTOR; the disease is Birt-Hogg-Dubé syndrome.